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and a Bayesian network meta-analysis of log-hazard ratios was performed. The 
primary outcome of the network meta-analysis was the time to progression to Type 
2 diabetes mellitus. Results are presented as hazard ratios and the probabilities of 
treatment rankings. Results: 30 studies were included in the network meta-anal-
ysis. There was a reduced hazard of progression to Type 2 diabetes mellitus associ-
ated with all interventions versus standard care. The most effective interventions 
compared to standard care were diet plus pioglitazone (HR 0.17, 95% CrI [0.09, 0. 
33] ), glipizide (HR 0.16, 95% CrI [0.02, 1.62] ), diet plus exercise plus metformin 
plus rosiglitazone (HR 0.20, 95% CrI [0.11, 0.39] ), diet plus exercise plus orlistat (HR 
0.31, 95% CrI [0.16, 0.61] ) and diet plus exercise plus pedometer (HR 0.35 95% CrI 
[0.11, 1.14] ). The least effective intervention was ramipril (HR 0.91, 95% CrI [0.72, 
1.14] ). ConClusions: Pharmacological and lifestyle interventions are beneficial 
in reducing the risk of progression to Type 2 diabetes mellitus. Lifestyle interven-
tions require significant behaviour changes and this may be achieved through 
incentives such as the use of pedometers. Lifestyle interventions alone, whilst 
beneficial, are unlikely to be as effective as pharmacological interventions alone 
or in combination with lifestyle interventions. Adverse events and costs of 
pharmacological interventions should be taken into account when consider-
ing potential risks and benefits, and their cost-effectiveness relative to lifestyle 
interventions.
PDB22
New Meta-aNalysis of PatieNt-level Data oN efficacy aND 
HyPoglycaeMia witH iNsuliN glargiNe or NPH iNsuliN iN tyPe 2 
DiaBetes Mellitus (t2DM) accorDiNg to coNcoMitaNt oral tHeraPy
Owens D.R.1, Trayor L.2, Landgraf W.3, Mullins P.4
1Institute of Life Sciences, Swansea University, Swansea, UK, 2Sanofi US, Inc., Bridgewater, NJ, 
USA, 3Sanofi, Frankfurt, Germany, 4Department of Statistics, University of Auckland, Auckland, 
New Zealand
objeCtives: Previous meta-analyses show inconsistent results regarding benefits 
of insulin glargine (GLA) over NPH insulin (NPH) in terms of nocturnal hypogly-
caemia. We analysed standardized efficacy and safety outcomes in uncontrolled 
insulin-naïve subjects with T2DM treated with GLA or NPH according to the oral 
antidiabetic drug (OAD) to which insulin was added (sulfonylurea [SU] ± metformin 
[MET] ). Methods: Patient-level data from 4 Treat-To-Target (TTT) RCTs (FPG < 100 
mg/dL) of ≥ 24 weeks duration were pooled. HbA1c, weight, dose, and hypoglycaemia 
(overall and nocturnal, plasma glucose < 56 mg/dL) were assessed. Results: 2,091 
subjects were analysed; 49% male, mean age 57.8 years. SU-treated subjects had 
longer T2DM duration, higher baseline HbA1c, and were less obese than MET+SU-
treated subjects. Endpoint HbA1c values were similar for GLA and NPH overall (7.4 
vs 7.5%). Subjects adding GLA or NPH to MET+SU had numerically lower weight-
adjusted endpoint insulin doses (GLA 0.40 vs 0.44 U/kg; NPH 0.36 vs 0.42 U/kg), 
with less weight gain (GLA: +1.9 vs +3.7 kg; NPH: +1.8 vs +3.0 kg) versus subjects 
adding insulin to SU. Hypoglycaemia incidence (overall: odds ratio [OR] 0.79 [95% CI 
0.66−0.95]; P= 0.011, nocturnal: OR 0.64 [0.51−0.81]; P< 0.001) and event rates (over-
all: rate ratio [RR] 0.78 [0.65−0.93]; P= 0.006, nocturnal: RR 0.54 [0.42−0.69]; P< 0.001) 
were significantly lower in GLA-treated subjects versus NPH, irrespective of con-
comitant OAD. In general, higher hypoglycaemia incidences/rates were observed 
in the MET+SU groups versus the SU only groups. MET+SU-treated subjects were 
more likely to achieve HbA1c < 7.0% without overall hypoglycemia versus SU-treated 
subjects (GLA: 24.6 vs 16.1%; NPH: 24.2 vs 13.0%). ConClusions: In insulin-naive 
T2DM patients from 4 TTT RCTs, GLA significantly reduced overall and nocturnal 
hypoglycemia risk versus NPH, irrespective of concomitant OAD. Subjects adding 
GLA or NPH to MET+SU had better efficacy outcomes than those adding to SU only, 
with slightly increased hypoglycaemia risk.
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objeCtives: To determine the efficacy and safety of dipeptidyl peptidase-4 (DPP-
4) inhibitors in type 2 diabetes patients according to published data. Methods: 
A systematic review of randomized clinical trials (RCT) in MEDLINE, Cochrane, 
ISI WOK, SCOPUS and clinicaltrials. gov databases was performed. Eligible stud-
ies were RCT with a treatment duration of at least 24 weeks evaluating efficacy 
(HbA1c, fasting plasma glucose-FPG- and weight variation from baseline) and/or 
safety (hypoglycemia rate) of DPP4 inhibitors (linagliptin, saxagliptin, sitagliptin, 
vildagliptin) compared with placebo or non-insulin monotherapy or combination, 
published in English or Spanish until June 2013. A meta-analysis was conducted 
using a random effects model. Standardized mean difference (SMD) for efficacy 
variables and relative risk (RR) for safety variable with 95% confidence intervals 
(CI) were calculated. Results: Of the 4,582 publications retrieved, 3,807 were 
deleted by duplicate review, 581 by title/abstract review and 139 by criteria com-
pliance. Finally, 55 RCT were selected. DPP-4 inhibitor monotherapy was associ-
ated to greater reductions in HbA1c and FPG compared with placebo [SMD= -0.60, 
95% CI= -0.75; -0.46 and SMD= -0.51, 95% CI= -0.62; -0.39, respectively] while com-
pared with metformin the reductions were lower [SMD= 0.28, 95% CI= 0.20; 0.26 
and SMD= 0.36, 95% CI= 0.27; 0.44, respectively]. DPP-4 inhibitors added to met-
formin lowered HbA1c and FPG significantly more than metformin monotherapy 
[SMD= -0.52, 95% CI= -0.62; -0.41 and SMD= -0.41, 95% CI= -0.51; -0.30, respectively], 
and achieved a greater decrease in weight and hypoglycemia risk versus sulfo-
nylurea plus metformin [SMD= -0.55, 95% CI= -0.64; -0.45 y RR= 0.16, 95% CI= 0.11; 
0.21, respectively]. Moreover, the addition of DPP-4 inhibitors to sulfonylurea 
showed a greater reduction in HbA1c compared with sulfonylurea monother-
apy [SMD= -0.54, 95% CI= -0.70; -0.37]. ConClusions: DPP-4 inhibitors added to 
metformin achieved a better glycemic control compared with metformin mono-
Multivariate Cox model adjusted for propensity score and sensitivity analysis 
confirmed a reduced risk of treatment change for M-Sit versus M-SU with a rela-
tive risk of 0.70 [0.62; 0.78] (p< 0.0001). ConClusions: We observed an approxi-
mate two-fold increase in the median treatment maintenance duration in the 
met-Sit group versus the met-SU group. Given the observational design, confound-
ing factors on the primary outcome cannot be excluded. However, multivariate 
and sensitivity analyses showed no qualitative change in the principal finding, 
providing some confidence in the observed difference between the two dual 
therapies.
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objeCtives: To demonstrate the use and interpretation of alternative approaches 
to evaluate and understand inconsistency within network meta-analyses 
(NMA). Methods: A network meta-analysis was performed to compare the efficacy 
of once weekly dulaglutide 1.5mg to licensed doses of liraglutide, exenatide, lixi-
senatide, and albiglutide for the treatment of type 2 diabetes. The primary endpoint 
was reduction in HbA1c. To allow for potential heterogeneity, networks were strati-
fied by background therapy: add-on to metformin (MET) and add-on to metformin in 
combination with sulfonylurea and/or thiazolidinediones (MET±SU±TZD). Networks 
were further stratified by time of evaluation (16-36 weeks and 37-56 weeks). The 
‘node-splitting’ approach and models including treatment-by-design interaction 
effects (where ‘design’ refers to the study comparator set), were used to examine 
inconsistency. Results: For the 37-56 week add-on to MET network there were no 
trials linking to dulaglutide 1.5mg; therefore, a NMA could not be conducted. For the 
37-56 week combination network there were no comparisons for which there were 
both direct and indirect evidence. For the 16-36 week add-on to MET network, there 
were no comparisons with statistically significant inconsistency in HbA1c reduction 
in the node splitting model and no significant design by treatment interactions. For 
the 16-36 week add-on to Met±SU±TZD network there was statistically significant 
variation between the direct and indirect estimates for the comparison between 
glargine and placebo and the comparison between glargine with liraglutide 1.80mg. 
Further sensitivity analyses were conducted removing the LEAD 5 trial (comparing 
placebo, glargine and liraglutide 1.80mg) from the network. ConClusions: The 
node-splitting and treatment-by-design interaction models showed no evidence 
of inconsistency in the 16-36 week monotherapy network. Following removal of 
the LEAD 5 trial, the 16-36 week combination network also showed no evidence of 
inconsistency. The analyses were useful in investigating potential inconsistency 
across the network.
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objeCtives: To evaluate the pattern and clinical outcomes of insulin therapies 
compared to oral antidiabetic therapies in the management of T2DM. Methods: A 
retrospective cohort study of patients with T2DM attending the Mesaimeer Primary 
HealthCare Center in Doha, Qatar. Inclusion criteria included were adult patients 
with at least with T2DM for 12 months period. Exclusion criteria included were age 
below 18 yrs, T2DM history less than 1 year, pregnant women and patients with 
kidney/hepatic disease. Patients’ medical records were reviewed for a period of 
one year. Data collected included socio-demographic profiles, clinical and labora-
tory data, medication regimens, and regimen cost per year. Data were analyzed 
descriptively and using Chi-Square test with priori alpha level of 0.05. Results: A 
total of 295 patients with T2DM attending the primary health center were included 
in the study. Majority of the patients were male (n= 210, 71.2%), age between 25-64 
years old (n= 241, 82.3%) and obese (n= 163, 55.3%). Metformin was the most fre-
quently used oral anti-diabetic medication (89.8%), followed by gliclazide (30.6%) 
and sitagliptin (26.2%). 32.3% of the patients were on insulin at the end of the 12 
month follow-up period. The most common treatment regimen at both time points 
was oral dual therapy (28.3%), followed by oral monotherapy (21.3%) and triple oral 
therapy (20.2%). The mean HbA1c was 8.0+1.6% at both the beginning and end-
point of the 12 month follow-up period, indicating uncontrolled DM. Those patients 
receiving insulin-containing therapy had a significantly higher proportion of uncon-
trolled DM than those who did not receive insulin (98% vs. 81%; p< 0.001) at the 
endpoint of 12-month follow-up period. ConClusions: The findings of this study 
showed that T2DM patients attending primary health care clinics in Qatar were not 
achieving glycemic control.
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objeCtives: Individuals with impaired fasting glucose (IFG) or impaired glucose 
tolerance (IGT) have an increased risk of progression to Type 2 diabetes mellitus. 
The objective of this study was to quantify the effectiveness of lifestyle, pharma-
cological and surgical interventions in reducing the progression to Type 2 diabetes 
mellitus in people with IFG or IGT. Methods: A systematic review was carried out 
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objeCtives: Effective management of diabetes is the cornerstone for prevention 
of diabetic complications. However, how well the Finnish Current Care guideline 
for diabetes is implemented in practice is unknown. Combining local and nation-
wide patient registers provide a valuable resource for evaluating risks, benefits 
and costs. The purpose of this study was to identify how the Finnish electronic 
patient information systems and national registers can be used to explore the treat-
ment for patients with incident type 2 diabetes. Methods: Selected primary and 
specialty care organizations representing different geographical areas and patient 
information system providers were invited to participate in the study. Study per-
mits were obtained from several local and nationwide register holders. The study 
protocol was reviewed by the Ethical Review Board of Hospital District of Helsinki 
and Uusimaa. Results: Register linkage is accomplished using unique personal 
identification numbers. We collect nationwide data on prescriptions, hospital and 
primary care, reimbursed dental care, and the causes of death. Cost data are based 
on hospital benchmarking database, sickness allowances and rehabilitations. We 
use local registers as a source of information on diagnoses, medical procedures, 
prescriptions and contact types. High quality laboratory data are also included from 
several local providers. ConClusions: Register linkages enable longitudinal fol-
low-up of patients for research purposes in Finland. In our study a unique combined 
register database of diabetic patient cohort is created that improves the evaluation 
of prognosis and care of diabetic patients. This is a promising and versatile source 
for research in pharmacoepidemiology.
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objeCtives: Diabetes mellitus Typ2 (T2DM) is a metabolic disease characterized 
by hyperglycemia with a high risk-potential of microvascular and macrovascular 
complications. In addition to glycemic control important therapy targets are the 
prevention of hypoglycemia and weight gain as well as blood pressure control due 
to national guidelines (German Medical Association 2013). To describe the current 
state of T2DM epidemiology and therapeutic needs in Germany which is mandatory 
when submitting AMNOG dossiers. Methods: To describe epidemiology of diabetes 
a targeted literature research was conducted in PubMed in 2014 using the search 
terms (epidemiology OR incidence OR prevalence). To identify relevant comorbidity 
information the following terms were used (metabolic syndrome OR glycemic con-
trol OR hypoglycemia OR obesity OR blood pressure) and combined with AND dia-
betes AND Germany. PubMed research was supplemented by additional searches in 
guidelines in German/English. Results: The screening of the epidemiologic results 
identified nine relevant publications: two specified a T2DM-prevalence of 15.3% and 
14.7% (Wittchen et al 2007, Huppertz et al 2009) and two studies estimated a T2DM 
incidence of 15.8 per 1000 patient years (KORA, MONICA). Treatment prevalence 
increased from 5.9% in 1998 to 8.9% in 2007 related to the total population (Hauner 
2013). Arterial hypertension was the most frequent comorbity (83%) of T2DM (Hagen 
et al. 2010). In 2010, a disease management program in North Rhine showed that only 
15% of participants with T2DM achieved a BMI < 25 (Hagen et al. 2010). Long-term 
trials investigating the efficacy of antidiabetics on the prevention of macrovascular 
complications are limited (Drug Commission of German Medical Association 2009; 
Matthaei et al. 2009). ConClusions: While treatment prevalence is increasing and 
glycemic control seems to be sufficiently achieved a substantial unmet medical need 
is identified for antidiabetics with a significant effect on weight reduction and blood 
pressure control in patients with T2DM in Germany.
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objeCtives: The objective of this study was to understand the progression over 
time of physiological parameters, including HbA1c, body mass index (BMI), sys-
tolic blood pressure (SBP), total cholesterol, LDL-cholesterol, HDL-cholesterol and 
triglycerides, in type 1 diabetes mellitus (T1DM) patients to inform disease mod-
eling. Methods: This was a cross-sectional analysis of T1DM patients based on 
the IMS LifeLink Diabetes Cohort in France, which prospectively collects clinical, 
biological and treatment information from general practitioners. Patient age, gen-
der, year of diagnosis, BMI, HbA1c, cardiovascular risk factors, renal function and 
lab test results were collected at baseline and subsequent visits. Data were ana-
lyzed using R Studio. T1DM patients who visited their general physician between 
May 2011 and May 2014 and have received at least one insulin prescription were 
included in the analysis. Results: A cohort of 605 T1DM patients was included 
in this analysis. Forty-three percent of patients were male. Average patient age at 
first visit was 58 years of age. Mean HbA1c was 7.8%, mean SBP was 132 mmHg, 
and mean BMI was 27.6 kg/m2. Linear regression showed that BMI increased by 
0.092 kg/m2 (p< 0.001) for each additional year of age. SBP was projected to increase 
by 0.248 mmHg (p< 0.001) per additional year of age, LDL-cholesterol decreased by 
therapy, with a lower risk of hypoglycemia and without affecting weight versus 
sulfonilurea and metformin combination.
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objeCtives: The purpose of this study was to evaluate the effectiveness and safety 
of treatment with recombinant growth hormone (RGH) in children with GH defi-
ciency. Methods: This was an interventional study with 6 and 12 months follow-
up. Treatment was received by 15 children. The patients were receiving the RGH in 
0.033 mg/kg (0.1 Unit/kg) at the same time each day (9-10 pm) for period of 1 year. 
The effectiveness of treatment was evaluated based on change in growing speed, 
growth SDS and bone age maturation. Results: The mean age of children was 
9.5±3.6 years. In the given sample 6 children had MHPD, other 9 children had IGHD. 
There was a great improvement in absolute growth at 6 and 12 months period of 
treatment (p-0.001; p-0.001). The same was found for growth SDS (p-0.001; p-0.001). 
Effectiveness of RGH therapy on bone age maturation also showed great improve-
ment (p-0.001; p-0.001). The level of IGF-1 was increased (p-0.001; p-0.001); at 12 
months the level of IGF-1 reached to 248.72±70.7 ng/mL and remained consistently 
high. The same improvement was in IGF-pb3 levels (p-0.001; p-0.001). The lipidemic 
analysis showed that the blood cholesterol levels were from 3.21 to 12.39 mmol/L 
(norm 5.68±1.55 mmol/L) and the level of LDL - 1.3 to 10.86 mmol/L (norm 3.83±1.44 
mmol/L). During the treatment period we observed the significant improvement in 
cholesterol levels (p-0.001; p-0.001). High density lipoprotein and triglyceride levels 
did not change significantly (p. 0.05). ConClusions: It can be concluded that the 
treatment with RGH in patient with GH deficiency is beneficial as it normalized the 
levels of cholesterol and LDL. During the treatment there were no any changes in 
indicators of kidney’s function, indicators of liver’s function as well as the indicators 
of carbohydrate metabolism.
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objeCtives: To compare the differences of effectiveness, safety and patients’ 
subjective feelings for using different lengths of insulin pen-needle in diabetic 
patients. Methods: A retrospective analysis of relevant publications that were 
identified via electronic searches of databases using multiple search terms related 
to insulin pen-needle. Results: Totally, 21 literatures were included. Firstly, 
for the effectiveness, 85.71% of the studies suggested that there was no differ-
ence between longer and shorter needle in controlling HbA1c, 14.29% thought 
the shorter needle was better than the longer. No changes were observed with 
respect to fructosamine, glycated albumin and body mass index. Secondly, about 
the safety, all of the studies proved that the shorter needle was better in intra-
muscular injections, adverse device effects, subcutaneous lipodystrophy and barb 
phenomenon. 33.33% reported less hypoglycemic events, bleeding, bruising and 
needle bending with the shorter needle, the others showed no difference. All of 
the studies considered the shorter needle was undifferentiated with the longer in 
the needle break, hyperglycemia and lipohypertrophy. 6.25% have pointed out that 
the shorter needle was better than the longer in leakage, while 81.25% showed no 
difference in the length. Thirdly, in terms of subjective feelings, for convenience 
and acceptance, all studies agreed that shorter needle was superior to the longer. 
For fear and pain, half of studies suggested that shorter needle was superior to the 
longer one; the other half thought that there was no difference. In all the studies, 
69.23% suggested patients prefer the shorter, 23.08% suggested the patients not 
prefer a particular needle length. ConClusions: Overall, the effectiveness of 
insulin pens with longer and shorter needle are comparable in treating diabetes, 
but the shorter needle is little better in parts of the safety indexes. As for patients’ 
subjective feeling, our findings show that patients are generally willing to accept 
shorter needle.
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objeCtives: To evaluate resource use and health costs due to the combination 
of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with dia-
betes and renal failure (RF) in routine clinical practice. Methods: An observa-
tional, retrospective study was performed. Patients aged ≥ 30 years treated with 
metformin who initiated a second oral antidiabetic treatment in 2008-2009 were 
included. Two groups of patients were analysed: a) metformin + DPP-4 inhibitors 
and b) other oral antidiabetics. The main measures were: compliance, persistence, 
metabolic control (glycosylated haemoglobin < 7%) and complications (hypogly-
cemia, cardiovascular events) and total costs. Patients were followed up for two 
years. Results: We included 395 patients, mean age 70.2 years, 56.5% male: 135 
patients received metformin + DPP-4 inhibitors and 260 patients received met-
formin + other oral diabetics. Patients receiving DPP-4 inhibitors showed better 
compliance (66.0% vs. 60.1%), persistence (57.6% vs. 50.0%) and metabolic control 
(63.9% vs. 57.3%), respectively, compared with those receiving other oral diabetics 
(p < 0.05), and also had a lower rate of hypoglycemia (20.0% vs. 47.7%) and lower 
total costs (€ 2,486 vs. € 3,002), p = 0.001. ConClusions: Despite the limitations 
of the study, patients with renal failure treated with DPP-4 inhibitors had better 
metabolic control, lower rates of hypoglycaemia, and lower health costs for the 
Spanish national health system.
